
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is supported by a broadened revenue base and clearer partner economics, as 3Q delivered $68M of topline, $6.1M of Sanofi royalties, and $42.6M of licensing revenue while FY26 revenue guidance was raised to $385M-$415M. The Sanofi collaboration de-risks the story by triggering a $125M milestone in 4Q and confirming a US Ph3 start in 2027, which could unlock another $225M on first commercial sale, even as non-GAAP breakeven shifts to early 2029. Beyond COVID, its Matrix-M platform and wholly owned pipeline add optionality, with a lead C. diff candidate targeting clinic entry as early as 2027 and cash of $627M, or $676M with receivables, funding operations into 2029.
Bears say
Novavax is facing a weakened 2027 revenue bridge as APA product sales drop out, R&D reimbursement falls to about $5M, and Sanofi upfront amortization declines to under $5M, leaving heavier reliance on royalties, supply, and a $75M technology transfer milestone expected in 3Q27. The company’s outlook is also exposed to execution risk because Sanofi controls SP0287 Phase 3 timing, delayed milestones could push it toward dilutive financing despite more than $700M of cash and securities, and in-the-money converts add about 22M shares. Competitive pressure from Pfizer/BioNTech and Moderna, possible regulatory demands beyond the assumed immunogenicity path, and patent challenges on Matrix-M further weaken the durability of its revenue base and partnership value.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Novavax (NVAX) Forecast
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares